Physician profile
Ayham Deeb
NPI 1700175288
$2,860.44
in general payments reported to CMS, 2019-2025
24 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $97.72 · 2021: $245 · 2022: $317 · 2023: $136 · 2024: $458 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $246.36 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $210.45 | 2022-2024 | Onureg, Opdivo |
| Novartis Pharmaceuticals Corporation | $193.06 | 2019-2020 | |
| Emd Serono, INC. | $189.53 | 2022-2024 | |
| Pfizer INC. | $169.30 | 2023-2025 | |
| Seagen INC. | $162.12 | 2019-2023 | Adcetris |
| Array Biopharma INC | $150.00 | 2025 | Mektovi, Lorbrena, Braftovi |
| Syndax Pharmaceuticals, INC. | $146.99 | 2025 | Revuforj |
| Stemline Therapeutics INC. | $126.47 | 2021 | |
| Sobi, INC | $125.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $124.93 | 2024 | Onivyde |
| Incyte Corporation | $116.60 | 2025 | Jakafi |
| Astrazeneca Pharmaceuticals Lp | $109.55 | 2022 | |
| Agios Pharmaceuticals, INC. | $107.08 | 2025 | Pyrukynd |
| Kite Pharma, INC. | $96.84 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galvanize Therapeutics, INC | $96.44 | 2025 | Aliya System |
| Amgen INC. | $96.42 | 2019 | |
| Merck Sharp & Dohme LLC | $94.49 | 2019 | |
| Genzyme Corporation | $91.88 | 2021 | |
| Intuitive Surgical, INC. | $91.33 | 2022 | |
| Rigel Pharmaceuticals, INC. | $66.67 | 2019 | |
| Abbvie INC. | $22.78 | 2024 | |
| Daiichi Sankyo INC. | $14.23 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayham Deeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.